Compare Mondaycom Ltd (MNDY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Neurocrine Biosciences Inc — how do they compare? Mondaycom Ltd trades at $73.54 (market cap $3.24B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.4× Mondaycom Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| MNDY | NBIX | |
|---|---|---|
Market Cap | $3.24B | $17.40B |
Sector | Technology | Health |
52-Week High | $292.24 | $180.55 |
52-Week Low | $58.81 | $123.10 |
Enterprise Value | $2.21B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $76.75, down 2.47% on the day, reflecting recent bearish pressure. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.15 versus $0.96 expected. Revenue reached $1.23 billion in 2025 with a net income margin of 9.17%. Technical indicators signal a bearish trend, with the price near key support at $75. The company announced Q2 2026 results will be reported on August 10, 2026 (Business Wire, 2026-07-20).
The investment outlook is mixed: strong analyst consensus (76% buy ratings) and a $115.50 price target suggest significant upside, but technical weakness and a high EV/EBITDA of 97.72 pose risks. Earnings growth and AI integration present opportunities, while market volatility and competitive pressures remain concerns.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
